Last reviewed · How we verify

BNT162b7 Bivalent (Original/OMI BA.4/BA.5) (bnt162b7-bivalent-original-omi-ba-4-ba-5)

Pfizer · FDA-approved active Quality 55/100

BNT162b7 Bivalent is a mRNA-based vaccine targeting SARS-CoV-2 spike protein.

BNT162b7 Bivalent (Original/OMI BA.4/BA.5) by Pfizer holds a significant market position as a leading mRNA-based vaccine, though it has not been the world's best-selling drug. The vaccine's competitive advantage lies in its bivalent formulation, which targets both the original SARS-CoV-2 strain and the Omicron BA.4/BA.5 subvariants, offering broader protection compared to monovalent vaccines. However, a key risk is the presence of strong competition from Moderna’s mRNA-1273.222, which has demonstrated greater efficacy in preventing COVID-19-related hospitalizations and outpatient encounters. Looking ahead, the pipeline for BNT162b7 Bivalent does not include any ongoing clinical trials, suggesting a focus on current market penetration and potential future adaptations to emerging variants.

At a glance

Generic namebnt162b7-bivalent-original-omi-ba-4-ba-5
SponsorPfizer
Drug classmRNA vaccine
TargetSARS-CoV-2 spike protein
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

BNT162b7 Bivalent is a type of mRNA vaccine, which uses a piece of genetic material called messenger RNA to instruct cells in the body to produce a specific protein. In this case, the protein is the SARS-CoV-2 spike protein, which is found on the surface of the COVID-19 virus. The vaccine works by stimulating the body's immune system to produce antibodies and immune cells that can recognize and fight the virus. This provides protection against COVID-19 infection.

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: